Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Atara Biotherapeutics, Inc.ATRA · Entity 6828 | Director · Chief Executive Officer | May 29, 2019 | May 31, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Atara Biotherapeutics, Inc.
Report date May 29, 2019 · Filed May 31, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 290,687 |
Last balance in matching sequence
After 2019-05-30 transaction · row 4
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
4 source rowsRow 1 · 2019-05-29 · Sale · Disposed 2,200 · Balance 294,337 F1: Transaction pursuant to Rule 10b5-1 Plan adopted January 23, 2018. F2: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $22.21 to $23.19. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Row 2 · 2019-05-29 · Sale · Disposed 725 · Balance 293,612 F1: Transaction pursuant to Rule 10b5-1 Plan adopted January 23, 2018. F4: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $23.23 to $23.335. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Row 3 · 2019-05-30 · Sale · Disposed 1,425 · Balance 292,187 F1: Transaction pursuant to Rule 10b5-1 Plan adopted January 23, 2018. F5: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $22.48 to $23.365. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Row 4 · 2019-05-30 · Sale · Disposed 1,500 · Balance 290,687 F1: Transaction pursuant to Rule 10b5-1 Plan adopted January 23, 2018. F6: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $23.54 to $23.80. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. |
| Common StockSEC Table I · non-derivative | Direct | 332,243 |
Reported balance
Holding disclosure · report date 2019-05-29 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 332,243 |
Filing footnotes · ownership attribution and instrument terms
F1: Transaction pursuant to Rule 10b5-1 Plan adopted January 23, 2018.
F2: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $22.21 to $23.19. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F3: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee.
F4: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $23.23 to $23.335. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F5: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $22.48 to $23.365. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F6: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $23.54 to $23.80. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 14, 2018 Filed Nov 15, 2018 19:06 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 600 | $34.51 | $20,706.00 |
DisclosureSEC source: 0001209191-18-058820 · doc4.xml · nonDerivative · entry 2 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 39,178 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted January 23, 2018. F4 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $34.25 to $34.61. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| November 14, 2018 Filed Nov 15, 2018 19:06 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 3,300 | $33.89 | $111,837.00 |
DisclosureSEC source: 0001209191-18-058820 · doc4.xml · nonDerivative · entry 1 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 39,778 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted January 23, 2018. F2 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $33.18 to $34.16. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| October 23, 2018 Filed Oct 23, 2018 18:10 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 800 | $35.18 | $28,144.00 |
DisclosureSEC source: 0001209191-18-055990 · doc4.xml · nonDerivative · entry 5 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 43,078 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted January 23, 2018. F7 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $34.92 to $35.43. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| October 23, 2018 Filed Oct 23, 2018 18:10 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 1,700 | $34.39 | $58,463.00 |
DisclosureSEC source: 0001209191-18-055990 · doc4.xml · nonDerivative · entry 4 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 43,878 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted January 23, 2018. F6 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $33.77 to $34.68. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| October 23, 2018 Filed Oct 23, 2018 18:10 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 1,400 | $33.17 | $46,438.00 |
DisclosureSEC source: 0001209191-18-055990 · doc4.xml · nonDerivative · entry 3 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 45,578 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted January 23, 2018. F5 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $32.75 to $33.44. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| October 22, 2018 Filed Oct 23, 2018 18:10 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 795 | $34.26 | $27,236.70 |
DisclosureSEC source: 0001209191-18-055990 · doc4.xml · nonDerivative · entry 2 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 46,978 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted January 23, 2018. F4 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $34.11 to $34.47. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| October 22, 2018 Filed Oct 23, 2018 18:10 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 3,105 | $33.66 | $104,514.30 |
DisclosureSEC source: 0001209191-18-055990 · doc4.xml · nonDerivative · entry 1 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 47,773 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted January 23, 2018. F2 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $33.09 to $34.06. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| October 05, 2018 Filed Oct 5, 2018 19:45 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 100 | $41.00 | $4,100.00 |
DisclosureSEC source: 0001209191-18-054455 · doc4.xml · nonDerivative · entry 5 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 50,878 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted January 23, 2018. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| October 05, 2018 Filed Oct 5, 2018 19:45 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 1,900 | $40.25 | $76,475.00 |
DisclosureSEC source: 0001209191-18-054455 · doc4.xml · nonDerivative · entry 4 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 50,978 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted January 23, 2018. F6 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $39.88 to $40.51. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| October 05, 2018 Filed Oct 5, 2018 19:45 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 1,900 | $39.58 | $75,202.00 |
DisclosureSEC source: 0001209191-18-054455 · doc4.xml · nonDerivative · entry 3 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 52,878 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted January 23, 2018. F5 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $38.84 to $39.84. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| October 04, 2018 Filed Oct 5, 2018 19:45 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 1,300 | $41.34 | $53,742.00 |
DisclosureSEC source: 0001209191-18-054455 · doc4.xml · nonDerivative · entry 2 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 54,778 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted January 23, 2018. F4 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $41.00 to $41.65. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| October 04, 2018 Filed Oct 5, 2018 19:45 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 2,600 | $40.09 | $104,234.00 |
DisclosureSEC source: 0001209191-18-054455 · doc4.xml · nonDerivative · entry 1 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 56,078 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted January 23, 2018. F2 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $39.50 to $40.50. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| September 22, 2018 Filed Sep 25, 2018 16:17 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Tax withholdingCommon Stock | 79,328 | $39.85 | $3,161,220.80 |
DisclosureSEC source: 0001209191-18-052146 · doc4.xml · nonDerivative · entry 1 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 733,285 F1 · kind: Shares sold to cover tax obligation from settlement of vested restricted stock units. Read SEC document |
| September 19, 2018 Filed Sep 20, 2018 16:26 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 3,900 | $39.99 | $155,961.00 |
DisclosureSEC source: 0001209191-18-051790 · doc4.xml · nonDerivative · entry 2 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 58,678 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted January 23, 2018. F4 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $39.675 to $40.55. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| September 18, 2018 Filed Sep 20, 2018 16:26 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 3,900 | $39.62 | $154,518.00 |
DisclosureSEC source: 0001209191-18-051790 · doc4.xml · nonDerivative · entry 1 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 62,578 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted January 23, 2018. F2 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $39.25 to $40.125. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| September 07, 2018 Filed Sep 10, 2018 16:19 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 1,827 | $40.23 | $73,500.21 |
DisclosureSEC source: 0001209191-18-050256 · doc4.xml · nonDerivative · entry 4 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 66,478 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted January 23, 2018. F6 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $40.15 to $40.40. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| September 07, 2018 Filed Sep 10, 2018 16:19 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 2,073 | $39.74 | $82,381.02 |
DisclosureSEC source: 0001209191-18-050256 · doc4.xml · nonDerivative · entry 3 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 68,305 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted January 23, 2018. F5 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $39.10 to $40.10. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| September 06, 2018 Filed Sep 10, 2018 16:19 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 1,120 | $39.42 | $44,150.40 |
DisclosureSEC source: 0001209191-18-050256 · doc4.xml · nonDerivative · entry 2 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 70,378 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted January 23, 2018. F4 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $39.25 to $39.90. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| September 06, 2018 Filed Sep 10, 2018 16:19 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 2,780 | $38.45 | $106,891.00 |
DisclosureSEC source: 0001209191-18-050256 · doc4.xml · nonDerivative · entry 1 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 71,498 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted January 23, 2018. F2 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $38.05 to $39.00. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| August 21, 2018 Filed Aug 22, 2018 16:19 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 3,900 | $36.69 | $143,091.00 |
DisclosureSEC source: 0001209191-18-047937 · doc4.xml · nonDerivative · entry 2 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 74,278 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted January 23, 2018. F4 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $36.35 to $37. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| August 20, 2018 Filed Aug 22, 2018 16:19 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 3,900 | $36.04 | $140,556.00 |
DisclosureSEC source: 0001209191-18-047937 · doc4.xml · nonDerivative · entry 1 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 78,178 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted January 23, 2018. F2 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $35.60 to $36.45. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| August 07, 2018 Filed Aug 7, 2018 17:56 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 300 | $37.75 | $11,325.00 |
DisclosureSEC source: 0001209191-18-045749 · doc4.xml · nonDerivative · entry 3 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 82,078 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted January 23, 2018. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| August 07, 2018 Filed Aug 7, 2018 17:56 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 3,600 | $37.35 | $134,460.00 |
DisclosureSEC source: 0001209191-18-045749 · doc4.xml · nonDerivative · entry 2 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 82,378 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted January 23, 2018. F4 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $36.70 to $37.70. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| August 06, 2018 Filed Aug 7, 2018 17:56 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 3,900 | $37.48 | $146,172.00 |
DisclosureSEC source: 0001209191-18-045749 · doc4.xml · nonDerivative · entry 1 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 85,978 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted January 23, 2018. F2 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $36.90 to $37.85. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| July 27, 2018 Filed Jul 30, 2018 16:43 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 1,700 | $37.53 | $63,801.00 |
DisclosureSEC source: 0001209191-18-044412 · doc4.xml · nonDerivative · entry 4 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 89,878 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted January 23, 2018. F5 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $37.20 to $37.95. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| July 27, 2018 Filed Jul 30, 2018 16:43 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 2,200 | $36.55 | $80,410.00 |
DisclosureSEC source: 0001209191-18-044412 · doc4.xml · nonDerivative · entry 3 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 91,578 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted January 23, 2018. F4 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $36.00 to $36.825. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| July 26, 2018 Filed Jul 30, 2018 16:43 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 100 | $39.45 | $3,945.00 |
DisclosureSEC source: 0001209191-18-044412 · doc4.xml · nonDerivative · entry 2 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 93,778 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted January 23, 2018. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| July 26, 2018 Filed Jul 30, 2018 16:43 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 3,800 | $39.02 | $148,276.00 |
DisclosureSEC source: 0001209191-18-044412 · doc4.xml · nonDerivative · entry 1 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 93,878 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted January 23, 2018. F2 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $38.40 to $39.35. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| July 10, 2018 Filed Jul 11, 2018 16:09 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 6,100 | $40.54 | $247,294.00 |
DisclosureSEC source: 0001209191-18-042311 · doc4.xml · nonDerivative · entry 4 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 97,678 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted January 23, 2018. F6 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $40.325 to $41.15. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| July 10, 2018 Filed Jul 11, 2018 16:09 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 22,300 | $39.93 | $890,439.00 |
DisclosureSEC source: 0001209191-18-042311 · doc4.xml · nonDerivative · entry 3 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 103,778 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted January 23, 2018. F5 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $39.30 to $40.30. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| July 09, 2018 Filed Jul 11, 2018 16:09 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 2,141 | $40.63 | $86,988.83 |
DisclosureSEC source: 0001209191-18-042311 · doc4.xml · nonDerivative · entry 2 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 126,078 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted January 23, 2018. F4 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $40.475 to $41.20. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| July 09, 2018 Filed Jul 11, 2018 16:09 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 27,859 | $39.88 | $1,111,016.92 |
DisclosureSEC source: 0001209191-18-042311 · doc4.xml · nonDerivative · entry 1 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 128,219 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted January 23, 2018. F2 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $39.45 to $40.45. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| June 27, 2018 Filed Jun 27, 2018 19:15 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 500 | $39.40 | $19,700.00 |
DisclosureSEC source: 0001209191-18-039715 · doc4.xml · nonDerivative · entry 4 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 156,078 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted May 18, 2017. F6 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $38.80 to $39.55. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| June 27, 2018 Filed Jun 27, 2018 19:15 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 1,500 | $37.57 | $56,355.00 |
DisclosureSEC source: 0001209191-18-039715 · doc4.xml · nonDerivative · entry 3 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 156,578 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted May 18, 2017. F5 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $37.05 to $38.05. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| June 26, 2018 Filed Jun 27, 2018 19:15 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 1,700 | $40.79 | $69,343.00 |
DisclosureSEC source: 0001209191-18-039715 · doc4.xml · nonDerivative · entry 2 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 158,078 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted May 18, 2017. F4 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $40.65 to $40.90. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| June 26, 2018 Filed Jun 27, 2018 19:15 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 2,700 | $40.01 | $108,027.00 |
DisclosureSEC source: 0001209191-18-039715 · doc4.xml · nonDerivative · entry 1 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 159,778 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted May 18, 2017. F2 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $39.50 to $40.40. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| June 06, 2018 Filed Jun 6, 2018 19:18 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 1,000 | $48.59 | $48,590.00 |
DisclosureSEC source: 0001209191-18-036168 · doc4.xml · nonDerivative · entry 5 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 162,478 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted May 18, 2017. F7 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $48.30 to $48.875. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| June 06, 2018 Filed Jun 6, 2018 19:18 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 1,500 | $47.69 | $71,535.00 |
DisclosureSEC source: 0001209191-18-036168 · doc4.xml · nonDerivative · entry 4 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 163,478 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted May 18, 2017. F6 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $47.20 to $48.20. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| June 06, 2018 Filed Jun 6, 2018 19:18 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 1,900 | $46.53 | $88,407.00 |
DisclosureSEC source: 0001209191-18-036168 · doc4.xml · nonDerivative · entry 3 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 164,978 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted May 18, 2017. F5 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $46.15 to $47.075. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| June 05, 2018 Filed Jun 6, 2018 19:18 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 1,200 | $50.27 | $60,324.00 |
DisclosureSEC source: 0001209191-18-036168 · doc4.xml · nonDerivative · entry 2 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 166,878 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted May 18, 2017. F4 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $50.05 to $50.55. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| June 05, 2018 Filed Jun 6, 2018 19:18 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 3,200 | $49.51 | $158,432.00 |
DisclosureSEC source: 0001209191-18-036168 · doc4.xml · nonDerivative · entry 1 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 168,078 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted May 18, 2017. F2 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $49.00 to $50.00. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| May 22, 2018 Filed May 22, 2018 19:02 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 4,400 | $50.88 | $223,872.00 |
DisclosureSEC source: 0001209191-18-032447 · doc4.xml · nonDerivative · entry 4 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 171,278 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted May 18, 2017. F6 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $50.35 to $51.25. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| May 21, 2018 Filed May 22, 2018 19:02 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 900 | $53.64 | $48,276.00 |
DisclosureSEC source: 0001209191-18-032447 · doc4.xml · nonDerivative · entry 3 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 175,678 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted May 18, 2017. F5 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $53.45 to $53.825. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| May 21, 2018 Filed May 22, 2018 19:02 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 2,000 | $52.83 | $105,660.00 |
DisclosureSEC source: 0001209191-18-032447 · doc4.xml · nonDerivative · entry 2 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 176,578 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted May 18, 2017. F4 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $52.40 to $53.40. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| May 21, 2018 Filed May 22, 2018 19:02 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 1,500 | $51.67 | $77,505.00 |
DisclosureSEC source: 0001209191-18-032447 · doc4.xml · nonDerivative · entry 1 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 178,578 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted May 18, 2017. F2 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $51.35 to $52.15. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| May 10, 2018 Filed May 10, 2018 19:46 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 2,200 | $40.98 | $90,156.00 |
DisclosureSEC source: 0001209191-18-029380 · doc4.xml · nonDerivative · entry 4 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 180,078 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted May 18, 2017. F6 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $40.75 to $41.20. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| May 10, 2018 Filed May 10, 2018 19:46 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 2,200 | $40.08 | $88,176.00 |
DisclosureSEC source: 0001209191-18-029380 · doc4.xml · nonDerivative · entry 3 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 182,278 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted May 18, 2017. F5 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $39.70 to $40.65. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| May 09, 2018 Filed May 10, 2018 19:46 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 3,100 | $39.50 | $122,450.00 |
DisclosureSEC source: 0001209191-18-029380 · doc4.xml · nonDerivative · entry 2 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 184,478 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted May 18, 2017. F4 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $39.025 to $39.90. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| May 09, 2018 Filed May 10, 2018 19:46 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 1,300 | $38.35 | $49,855.00 |
DisclosureSEC source: 0001209191-18-029380 · doc4.xml · nonDerivative · entry 1 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 187,578 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted May 18, 2017. F2 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $38.00 to $38.80. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
| April 27, 2018 Filed Apr 30, 2018 16:15 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 500 | $43.95 | $21,975.00 |
DisclosureSEC source: 0001209191-18-026838 · doc4.xml · nonDerivative · entry 4 Ciechanover Isaac E. · CIK 0001612096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 188,878 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted May 18, 2017. F6 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $43.75 to $44.00. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.nature: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.